ARCHIVES

Phase II Imbruvica Trial Shows 47% of MCL Patients Alive at 27-Month Median Follow-up

This article is from The Cancer Letter archive.

Vol. 37 No. 12 | December 26, 2014

Download PDF Visit The Full Archive

Related Articles

Sullivan Accuses Tobacco Industry With “Lies, Blue smoke And Mirrors”

June 15, 1990

Six Patients Apparently responded To Laetrile, NCI Review Finds; DCT Considers Clinical Trials

September 8, 1978

First TIL Results: Four Patients, All Responded, One Complete; Panel Pens Reauthorization Drive

November 27, 1987

Breast cancer session was ASCO equivalent of a rock concert, discussant says.

May 27, 2005

FDA, Genentech Agree On Framework for Avastin Hearing June 28-29

April 8, 2011

In Brief: FDA Seeks Applicants For Oncology Div. Head; Croce Wins Pasarow Award; CRI Honors Five

August 18, 1995